Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Radiation: Standard radiotherapy
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 62
- Registration Number
- NCT00796718
CLEAR Study - A Study of CellCept (Mycophenolate Mofetil) in Recipients of Kidney Transplants
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 136
- Registration Number
- NCT00788567
Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection
Phase 1
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- Drug: ANA598 200 mg bid or placeboDrug: ANA598 400 mg bid or placeboDrug: ANA598 800 mg bid or placebo
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 35
- Registration Number
- NCT00782353
- Locations
- 🇺🇸
United States, Missouri, St. Louis, Missouri, United States
🇺🇸United States, New York, New York, New York, United States
🇵🇷Puerto Rico, Santurce, Santurce, Puerto Rico
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT00778102
A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
Phase 1
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1
- Registration Number
- NCT00776698
A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 117
- Registration Number
- NCT00776425
PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00774241
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 150
- Registration Number
- NCT00773695
- Locations
- 🇳🇴
Ullevael Sykehus; Dept of Oncology, Oslo, Norway
🇳🇴The Norvegian Radium Hospital Montebello; Dept of Oncology, Oslo, Norway
🇳🇴St. Olavs Hospital; Kreftavdelingen, Trondheim, Norway
A Study of Monthly Subcutaneous Continuous Erythropoietin Receptor Activator (CERA) in Predialysis Participants With Chronic Renal Anemia
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT00773968
A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT00773526
© Copyright 2025. All Rights Reserved by MedPath